Results 161 to 170 of about 104,823 (289)

Impact of delayed appointments on treatment outcomes in neovascular macular degeneration

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola   +3 more
wiley   +1 more source

Immediate effect of intravitreal injection of bevacizumab on intraocular pressure

open access: yes, 2014
Ricardo Lemos-Reis,1 Nuno Moreira-Gonçalves,1 António B Melo,1 Ângela M Carneiro,1,2 Fernando M Falcão-Reis1,2 1Department of Ophthalmology of Hospital de São João, Porto, Portugal; 2Department of Sense Organs ...
Lemos-Reis R   +4 more
core  

New perspectives on VEGF signalling in Alzheimer's disease

open access: yesBrain Pathology, EarlyView.
Emery et al. bring together findings from recent multi‐omic studies, including single‐cell mRNA analysis of human post‐mortem brain tissue, and proteomic analysis of matched CSF and blood samples in large clinical studies. The authors present evidence of the involvement of altered VEGF signalling in vascular and immune dysfunction and neurodegeneration
Cherelle E. G. Emery   +2 more
wiley   +1 more source

Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle

open access: yes, 2013
Raluca Rusovici, Chirag J Patel, Kakarla V ChalamUniversity of Florida, Department of Ophthalmology, Jacksonville, FL, USABackground: The purpose of this study was to evaluate cell cycle changes in choroidal endothelial cells treated with varying doses ...
Patel CJ, Rusovici R, Chalam KV
core  

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. [PDF]

open access: yesThorac Cancer
Yamauchi K   +24 more
europepmc   +1 more source

Acute sterile endophthalmitis following intravitreal bevacizumab: case series

open access: yes, 2014
Axel Orozco-Hernández,1 Ximena Ortega-Larrocea,1 Gustavo Sánchez-Bermúdez,1 Gerardo García-Aguirre,1 Virgilio Morales Cantón,1 Raul Velez-Montoya2 1Retina Department, Asociación para Evitar la Ceguera en M ...
Ortega-Larrocea X   +5 more
core  

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

open access: yesBritish Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy